Skip to main content

Emma Börgeson

Universitetslektor, biträdande

Department of Molecular and Clinical
Visiting address
Blå stråket 5 b wallenberglab/su
41345 Göteborg
Postal address
Su sahlgrenska
41345 Göteborg

About Emma Börgeson

Assistant Professor, Principal Investigator

Emma Börgeson is an assistant professor in the Department of Molecular and Clinical Medicine. She joined the faculty as a tenure-track fellow in the Wallenberg Centre for Molecular and Translational Medicine (WCMTM) at Gothenburg University. Dr. Börgeson leads a small but dedicated translational research team, investigating the therapeutic potential of immunomodulation in obesity-related cardiometabolic pathophysiology.

After completing her PhD in medicine at University College Dublin in 2011, Dr Börgeson received a Marie Curie fellowship from the European Commission to do a three-year post doc at the University of San Diego (UCSD). There, she investigated the therapeutic potential of immunomodulation in models of obesity, with a particular focus on chronic kidney disease. Her current research focus is to identify the anti-inflammatory mechanisms that control obesity-related cardiometabolic disease and to translate these findings to human pathophysiology.

Emma Börgeson has received numerous honors and awards.

Honors & Awards

  • Junior Investigator Award, International Conference on Phospholipase A2 and Lipid Mediators, San Diego. 2016
  • Emerging Leaders in Nutritional Sciences, Experimental Biology, San Diego. 2016
  • Nominated for the Hasselblad Foundation Award for women scientists, Sweden. 2015
  • Highlighted poster, Bioactive Lipids in Inflammation & Diseases, Puerto Rico. 2013
  • Nominated for Roche National Researcher of the Year, Ireland. 2013
  • Honorary Directors Prize due to special distinction, UCD Conway festival, Ireland. 2013
  • Best moderated poster, Diabetes & Vascular biology, UCD Conway festival, Ireland. 2013
  • Best scientific presentation, Irish Society of Nephrology, Ireland. 2013
  • Outstanding junior career progression, ERA-EDTA ‘Molecular Targets in Renal Disease’ Symposia, Germany. 2011

Main Research

We are a translational research team, investigating the underlying disease mechanisms of obesity and cardiometabolic disease, with a special interest in inflammatory resolution.

Inflammation is a key driver of obesity-induced cardiometabolic pathophysiology and consists of two phases: an initial acute phase followed by a resolving phase. The latter is actively regulated by specialized pro-resolving lipid mediators (SPMs). Lipoxins are one group of SPMs that act through defined receptors to promote resolution of inflammation.

The overall aim of our research is to investigate and harness the therapeutic potential of lipoxins. Our studies suggest that treatment with lipoxins attenuates obesity-induced adipose inflammation and subsequent development of systemic disease (Börgeson et al, Cell Metabolism, 2015). We are currently investigating the underlying mechanisms that mediate this protection, and whether our results from preclinical models can be translated to human pathophysiology.

We combine experimental studies with clinical basic research to address our hypotheses in a translational manner. We use ex vivo culture of tissue biopsies, which provide valuable “proof-of-principle” evidence to correlate our experimental data with human physiology. This translational approach requires state-of-the art experimental and clinical facilities, as well as a broad network of expertise, made possible via our collaborators. For more information on our research, please visit Borgeson lab.

Group Members

  • Matúš Soták, PhD: Postdoctoral Fellow
  • Meenu Rohini Rajan, PhD: Postdoctoral Fellow
  • Fredrik Barrenäs, PhD: Senior Research Associate
  • Madison Clark: Undergraduate Researcher
  • Emelie Shehadeh: Undergraduate Researcher

Key Publications

Key original papers

Key review papers

For more information, please visit: Bö